Author

S. Kedia

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Biophysics· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Research Focus:cell signaling & trafficking· 2 Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Assay:imaging· 2 Organism:mouse· 2 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1

Frequent Co-Authors

V. Ahuja· 2 shared A. Deka· 1 shared A. K. Singh· 1 shared B. Banoth· 1 shared B. Chatterjee· 1 shared B. Li· 1 shared C. Bryant· 1 shared D. Klenerman· 1 shared

Activity by Year

2019-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 16 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

V. Ahuja

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

The delayed kinetics of Myddosome formation explains why Aβ aggregates trigger TLR4 less efficiently than LPS

B. Li, P. Suresh, J. Brelstaff, S. Kedia, C. Bryant, D. Klenerman

This study shows that Aβ aggregates trigger TLR4 less efficiently than LPS due to slower Myddosome formation and longer lifetimes of larger Myddosomes.

bioRxiv · Sep 28, 2023Biophysics

An epithelial Nfkb2 pathway exacerbates intestinal inflammation by supplementing latent RelA dimers to the canonical NF-κB module

M. Chawla, T. Mukherjee, A. Deka, B. Chatterjee, U. A. Sarkar, A. K. Singh, S. Kedia, B. Banoth, S. K. Biswas, V. Ahuja, S. Basak

The paper shows that noncanonical NF-κB signaling in intestinal epithelial cells enhances latent RelA dimers, amplifying canonical NF-κB activity and exacerbating intestinal inflammation in IBD.

bioRxiv · Nov 2, 2020Immunology

Mesenchymal stem cells (MSCs) offer a drug tolerant and immune-privileged niche to Mycobacterium tuberculosis

N. Jain, H. Kalam, L. Singh, V. Sharma, S. Kedia, P. Das, V. Ahuja, D. Kumar

This study shows mesenchymal stem cells (MSCs) provide a drug-tolerant and immune-privileged niche for Mycobacterium tuberculosis, with implications for tuberculosis treatment.

bioRxiv · Jan 16, 2019Immunology